Provided by Tiger Trade Technology Pte. Ltd.

Agios Pharmaceuticals

31.82
-0.1000-0.31%
Volume:223.35K
Turnover:7.12M
Market Cap:1.89B
PE:-4.54
High:32.15
Open:31.85
Low:31.53
Close:31.92
52wk High:46.00
52wk Low:22.24
Shares:59.47M
Float Shares:50.09M
Volume Ratio:0.42
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.0075
EPS(LYR):-7.1203
ROE:-34.34%
ROA:-22.24%
PB:1.84
PE(LYR):-4.47

Loading ...

Truist Financial Keeps Their Buy Rating on Agios Pharma (AGIO)

TIPRANKS
·
Jun 15

Agios Pharmaceuticals (AGIO) Is Up 7.4% After Mitapivat RISE UP Data in Sickle Cell Disease - Has The Bull Case Changed?

Simply Wall St.
·
Jun 15

Agios Pharmaceuticals price target raised to $54 from $50 at H.C. Wainwright

TIPRANKS
·
Jun 15

U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology

Reuters
·
Jun 15

Agios posts EHA 2026 investor event presentation on rare hematology pipeline

Reuters
·
Jun 15

Agios Pharmaceuticals presented results from Phase 3 trial of mitapivat

TIPRANKS
·
Jun 15

Agios says Phase 3 RISE UP trial shows mitapivat boosts hemoglobin response in sickle cell disease patients

Reuters
·
Jun 13

Agios Showcases Rise up Phase 3 Results at Eha 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

THOMSON REUTERS
·
Jun 13

Agios Pharmaceuticals Is Maintained at Neutral by JP Morgan

Dow Jones
·
Jun 11

U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle

Reuters
·
Jun 11

Agios Pharmaceuticals price target lowered to $31 from $36 at JPMorgan

TIPRANKS
·
Jun 11

Analysts Are Neutral on Top Healthcare Stocks: Stevanato Group (STVN), Agios Pharma (AGIO)

TIPRANKS
·
Jun 11

Agios Pharmaceuticals, Oscotec Sign Global Licensing Agreement for Cevidoplenib

MT Newswires Live
·
Jun 01

Agios posts investor deck on cevidoplenib licensing deal in immune thrombocytopenia (ITP)

Reuters
·
Jun 01

Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib

TIPRANKS
·
Jun 01

Agios licenses exclusive global rights from Oscotec to SYK inhibitor cevidoplenib in deal with USD 25 million upfront payment

Reuters
·
Jun 01

Agios Pharmaceuticals - Oscotec to Receive $25 Mln Upfront Plus Milestone Payments and Tiered Royalties

THOMSON REUTERS
·
Jun 01

Agios Pharmaceuticals - Oscotec Eligible for up to $140 Mln in Development and Regulatory Milestones

THOMSON REUTERS
·
Jun 01

Agios Pharmaceuticals - Oscotec Retains Option for Exclusive Rights to Cevidoplenib in South Korea

THOMSON REUTERS
·
Jun 01

Agios Pharmaceuticals - Expects 2026 Operating Expense Guidance to Be Flat Compared to 2025

THOMSON REUTERS
·
Jun 01